Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

On September 3, 2025 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, reported that Director and CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City (Press release, Enveric Biosciences, SEP 3, 2025, https://www.enveric.com/news/enveric-biosciences-to-present-at-h-c-wainwright-27th-annual-global-investment-conference/ [SID1234655727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the prerecorded presentation, Dr. Tucker will provide updates and discuss progress for the Company’s pipeline of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, including its lead candidate EB-003. Enveric designed EB-003 to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. EB-003 also offers a potential dual-targeting mechanism of action, with data demonstrating partial agonism at the 5-HT A receptor and agonism at the 5-HT B receptor.

Details of the presentation are as follows:

Event:

H.C. Wainwright 27th Annual Global Investment Conference

Date:

September 8-10, 2025

Virtual Presentation:

7:00 AM, ET, September 8, 2025

Registration:

View Source

During the conference, Dr. Tucker will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.